Drugs / Tetanus vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT03251924 Background | Sep 2017 → Dec 2021 | cancer | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02737475 Background | Jun 2016 → Nov 2020 | cancer of unknown primary site | Bristol-Myers Squibb | Completed | No outcome recorded |
| — | NCT02538211 Comparator | Sep 2015 → Jan 2017 | Rotavirus infection, post-bacterial disorder, streptococcal pneumonia, tetanus | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03251924 ↗ |
| Modality | Vaccine | “Tetanus vaccine” NCT02538211 ↗ |
| Route | Intramuscular | “intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.” NCT02538211 ↗ |